Drug Profile
Research programme: sexual dysfunction therapeutics - S1 Biopharma
Alternative Names: S1B-3006; S1B-307; S1P-401Latest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator S1 Pharmaceuticals
- Developer S1 Biopharma
- Class
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anorgasmia; Decreased libido; Female sexual dysfunction; Male sexual dysfunction
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Anorgasmia in USA (unspecified route) (S1 Biopharma pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Decreased libido in USA (unspecified route) (S1 Biopharma pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Female sexual dysfunction in USA (unspecified route) (S1 Biopharma pipeline, February 2023)